Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus and Mycophenolate for GvHD Prevention in Mismatched HSCT
NCT02728700Phase 1Terminated
- Sponsor
- Stanford University
- Start
- Feb 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sirolimus and mycophenolate mofetil in graft-versus-host disease (GVHD), sponsored by Stanford University. Primary endpoint: Incidence of acute graft-versus-host disease grade 3 & 4 at 60 days. Started Feb 2016; status: terminated.
02
Drugs
sirolimusmycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02728700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728700.